Johnson & Johnson, us and Varipulse
Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) and keeping the price ...
Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to ...
Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA therapy and 3D mapping for AFib treatment.
Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...
Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...
JNJ has an attractive 3.41% dividend yield comparable to the yield on long-term bonds. Given the lack of price movement and ...
Bernstein lowered the firm’s price target on Johnson & Johnson to $160 from $177 and keeps a Market Perform rating on the shares as part of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback